Why is Boston Scientific Stock Trading Lower On Wednesday?

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of open-heart surgery.

The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.

This randomized trial evaluated the ACURATE neo2 valve, the company’s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.

SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:EW), and Evolut is Medtronic Plc’s NYSE: MDT) brand.

The composite rate of all-cause mortality, stroke, or ...